Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 15/20 | 0.45 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.45 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659573 | 0.98 | ADRB2 (0.51) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL6525052 | 0.92 | STAT3 (0.42) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL12788269 | 0.91 | ADRB2 (0.50) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL3658326 | 0.90 | LIPG (0.45) | ADRB2STAT3PRKAA2 | |
| SCHEMBL3660709 | 0.90 | ADRB2 (0.52) | ADRB2STAT3PRKAA2MLNRCYP3A4 | |
| SCHEMBL3662088 | 0.88 | STAT3 (0.41) | ADRB2STAT3PRKAA2 | |
| SCHEMBL3654712 | 0.85 | GPR119 (0.40) | ADRB2STAT3PRKAA2 | |
| SCHEMBL3801414 | 0.85 | CHRM2 (0.41) | STAT3PRKAA2 | |
| SCHEMBL3807842 | 0.84 | CHRM2 (0.44) | STAT3PRKAA2 | |
| SCHEMBL3805215 | 0.84 | GPR119 (0.44) | ADRB2STAT3PRKAA2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | PROSIDION LIMITED (GB) | 2011-03-10 | — | — | US | disclosed |
| WO-2009050522-A1 | AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS | PROSIDION LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059942-A1 | Azetidinyl G-Protein Coupled Receptor Agonists | GPR119, GIPR, GPR39 | ADRB2 126/4885STAT3 1637/4885PRKAA2 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.